Uveitis Market Report and Forecast 2025-2034
Description
The uveitis market was valued at USD 700.34 Million in 2024 driven by the increasing prevalence of the autoimmune disease among the 8 major markets. It is expected to grow at a CAGR of 6.00% during the forecast period of 2025-2034 and attain a market value of USD 1254.20 Million by 2034.
Uveitis Market Overview
Uveitis is an inflammatory condition affecting the uvea of the eye, causing pain, redness, and sometimes blindness. The market for uveitis treatment includes anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is expected to be driven by the rise in autoimmune diseases and the emphasis associated with early diagnosis of the condition.
Uveitis Market Growth Drivers
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The rise in autoimmune diseases, such as rheumatoid arthritis and lupus, which are associated with secondary uveitis. These conditions often exacerbate ocular inflammation, thus, driving demand for uveitis treatments. According to the National Health Council, around 50 million Americans are affected by autoimmune diseases, with some research suggesting an annual rise of 3-12%, indicating that autoimmunity is becoming more prevalent. This growing challenge highlights the immediate need for innovative treatments and targeted solutions.
Uveitis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Rise in Combination Therapies
The trend of using corticosteroids, immunosuppressants, and biologics together is increasing in the treatment of uveitis, providing a more comprehensive approach to symptom management. This method is particularly effective in complex cases, reducing recurrence rates and enhancing patient outcomes. The trend towards combination treatments demonstrates a greater focus on tailored and thorough treatment approaches. The goal is to address various aspects of the condition to manage the disease over the long term.
Growing Emphasis on Early Diagnosis to Boost Uveitis Market Value
There is an increased focus on early diagnosis through improved screening methods, combined with heightened awareness. The demand for early-stage treatment and the availability of timely intervention options are driving market growth.
Targeted Therapies Strategies Expected to Propel Market Expansion
In April 2024, Priovant Therapeutics announced positive results from the NEPTUNE Phase 2 study evaluating brepocitinib for the treatment of non-anterior non-infectious uveitis (NIU). The study also showed significant improvements in secondary endpoints, such as visual acuity and macular edema resolution. Traditionally, steroid-based therapies have been used to manage NIU, but these come with risks like increased intraocular pressure. With brepocitinib, the market is shifting towards steroid-free targeted therapies, offering promising treatment options that support improved patient outcomes, while driving growth in the market.
Rising Utilization of Biologic Treatments in Uveitis Management
Biologic drugs are being used to treat uveitis owing to their unique mode of action that improves treatment outcomes and reduces side effects. Biologics are viewed as advanced treatment choices as they target specific immune responses, leading to more accurate and efficient symptom management.
Uveitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market because of their central role in managing the condition. Uveitis is predominantly characterized by inflammation, making anti-inflammatory treatments like corticosteroids and biologics the first choice for treatment. These treatments effectively reduce eye inflammation and protect against long-term damage.
Uveitis Market Analysis by Region
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from the presence of major healthcare and pharmaceutical companies in the region.
Leading Players in the Uveitis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Abbvie Inc.
AbbVie, based in North Chicago, USA, specializes in developing treatments for immunology and ophthalmology. Their product portfolio includes Humira (adalimumab), a biologic that suppresses the immune system and is utilized to treat autoimmune uveitis by decreasing inflammation.
Bausch Health Companies Inc.
Headquartered in Laval, Canada, Bausch Health provides a range of products designed for maintaining eye health. Bausch Health Companies acquired the rights to use XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) from Clearside Biomedical for the treatment of macular edema linked to uveitis.
Novartis AG
Based in Basel, Switzerland, Novartis holds a significant presence in the field of ophthalmology. The range of treatments they offer for uveitis includes Ilaris (canakinumab), a medication that inhibits interleukin-1 beta to address inflammation in the eye condition.
F. Hoffmann-La Roche AG
Roche, based in Basel, Switzerland, offers biologics such as Actemra (tocilizumab), an IL-6 inhibitor used off-label for uveitis treatment. Roche is dedicated to progressing its ophthalmic pipeline, which includes treatments for inflammatory eye conditions such as uveitis.
Other companies include EyePoint Pharmaceuticals, Inc., Alimera Sciences, Inc., Aldeyra Therapeutics, Inc., Lux Biosciences, Inc., Amgen Inc., and Santen Pharmaceutical Co., Ltd.
Key Questions Answered in the Uveitis Market
Uveitis Market Overview
Uveitis is an inflammatory condition affecting the uvea of the eye, causing pain, redness, and sometimes blindness. The market for uveitis treatment includes anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is expected to be driven by the rise in autoimmune diseases and the emphasis associated with early diagnosis of the condition.
Uveitis Market Growth Drivers
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The rise in autoimmune diseases, such as rheumatoid arthritis and lupus, which are associated with secondary uveitis. These conditions often exacerbate ocular inflammation, thus, driving demand for uveitis treatments. According to the National Health Council, around 50 million Americans are affected by autoimmune diseases, with some research suggesting an annual rise of 3-12%, indicating that autoimmunity is becoming more prevalent. This growing challenge highlights the immediate need for innovative treatments and targeted solutions.
Uveitis Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Rise in Combination Therapies
The trend of using corticosteroids, immunosuppressants, and biologics together is increasing in the treatment of uveitis, providing a more comprehensive approach to symptom management. This method is particularly effective in complex cases, reducing recurrence rates and enhancing patient outcomes. The trend towards combination treatments demonstrates a greater focus on tailored and thorough treatment approaches. The goal is to address various aspects of the condition to manage the disease over the long term.
Growing Emphasis on Early Diagnosis to Boost Uveitis Market Value
There is an increased focus on early diagnosis through improved screening methods, combined with heightened awareness. The demand for early-stage treatment and the availability of timely intervention options are driving market growth.
Targeted Therapies Strategies Expected to Propel Market Expansion
In April 2024, Priovant Therapeutics announced positive results from the NEPTUNE Phase 2 study evaluating brepocitinib for the treatment of non-anterior non-infectious uveitis (NIU). The study also showed significant improvements in secondary endpoints, such as visual acuity and macular edema resolution. Traditionally, steroid-based therapies have been used to manage NIU, but these come with risks like increased intraocular pressure. With brepocitinib, the market is shifting towards steroid-free targeted therapies, offering promising treatment options that support improved patient outcomes, while driving growth in the market.
Rising Utilization of Biologic Treatments in Uveitis Management
Biologic drugs are being used to treat uveitis owing to their unique mode of action that improves treatment outcomes and reduces side effects. Biologics are viewed as advanced treatment choices as they target specific immune responses, leading to more accurate and efficient symptom management.
Uveitis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Anterior Uveitis
- Posterior Uveitis
- Intermediate Uveitis
- Panuveitis
- Others
- Anti-inflammatory
- Immunosuppressive
- Antibiotics
- Others
- Oral
- Parenteral
- Others
- Hospital
- Homecare
- Specialty Clinics
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market because of their central role in managing the condition. Uveitis is predominantly characterized by inflammation, making anti-inflammatory treatments like corticosteroids and biologics the first choice for treatment. These treatments effectively reduce eye inflammation and protect against long-term damage.
Uveitis Market Analysis by Region
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from the presence of major healthcare and pharmaceutical companies in the region.
Leading Players in the Uveitis Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Abbvie Inc.
AbbVie, based in North Chicago, USA, specializes in developing treatments for immunology and ophthalmology. Their product portfolio includes Humira (adalimumab), a biologic that suppresses the immune system and is utilized to treat autoimmune uveitis by decreasing inflammation.
Bausch Health Companies Inc.
Headquartered in Laval, Canada, Bausch Health provides a range of products designed for maintaining eye health. Bausch Health Companies acquired the rights to use XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) from Clearside Biomedical for the treatment of macular edema linked to uveitis.
Novartis AG
Based in Basel, Switzerland, Novartis holds a significant presence in the field of ophthalmology. The range of treatments they offer for uveitis includes Ilaris (canakinumab), a medication that inhibits interleukin-1 beta to address inflammation in the eye condition.
F. Hoffmann-La Roche AG
Roche, based in Basel, Switzerland, offers biologics such as Actemra (tocilizumab), an IL-6 inhibitor used off-label for uveitis treatment. Roche is dedicated to progressing its ophthalmic pipeline, which includes treatments for inflammatory eye conditions such as uveitis.
Other companies include EyePoint Pharmaceuticals, Inc., Alimera Sciences, Inc., Aldeyra Therapeutics, Inc., Lux Biosciences, Inc., Amgen Inc., and Santen Pharmaceutical Co., Ltd.
Key Questions Answered in the Uveitis Market
- What was the uveitis market value in 2024?
- What is the uveitis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market breakup based on the treatment?
- What is the market segmentation based on the route of administration?
- What is the market segmentation based on the end user?
- What are the major factors aiding the uveitis market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major uveitis market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the uveitis market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- How does anterior uveitis compare to posterior uveitis in treatment demand?
- How are immunosuppressive treatments impacting the uveitis landscape?
- Which route of administration is most common for uveitis treatments?
- Which end-user segment is expected to grow the most in the uveitis market?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Uveitis Market Overview – 8 Major Markets
- 3.1 Uveitis Market Historical Value (2018-2024)
- 3.2 Uveitis Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Uveitis Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Dosage Form Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Dosage Form Success Rate
- 7 Uveitis Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Dosage Form Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Uveitis Market Landscape – 8 Major Markets
- 8.1 Uveitis Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Uveitis Market: Product Landscape
- 8.2.1 Analysis by Treatment Method
- 8.2.2 Analysis by Indication
- 8.2.3 Analysis by Route of Administration
- 9 Uveitis Market Challenges and Unmet Needs
- 9.1 Dosage Form Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Dosage Form
- 11 Uveitis Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Uveitis Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Uveitis Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Anterior Uveitis
- 12.1.3 Posterior Uveitis
- 12.1.4 Intermediate Uveitis
- 12.1.5 Panuveitis
- 12.1.6 Others
- 12.2 Uveitis Market (2018-2034) by Treatment
- 12.2.1 Market Overview
- 12.2.2 Anti-inflammatory
- 12.2.3 Immunosuppressive
- 12.2.4 Antibiotics
- 12.2.5 Others
- 12.3 Uveitis Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Uveitis Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospital
- 12.4.3 Homecare
- 12.4.4 Specialty Clinics
- 12.4.5 Others
- 12.5 Uveitis Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 United Kingdom
- 12.5.4 Germany
- 12.5.5 France
- 12.5.6 Italy
- 12.5.7 Spain
- 12.5.8 Japan
- 12.5.9 India
- 13 United States Uveitis Market (218-2034)
- 13.1 United States Uveitis Market Historical Value (2018-2024)
- 13.2 United States Uveitis Market Forecast Value (2025-2034)
- 13.3 United States Uveitis Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Anterior Uveitis
- 13.3.3 Posterior Uveitis
- 13.3.4 Intermediate Uveitis
- 13.3.5 Panuveitis
- 13.3.6 Others
- 13.4 Uveitis Market (2018-2034) by Treatment
- 13.4.1 Market Overview
- 13.4.2 Anti-inflammatory
- 13.4.3 Immunosuppressive
- 13.4.4 Antibiotics
- 13.4.5 Others
- 13.5 Uveitis Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 Uveitis Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospital
- 13.6.3 Homecare
- 13.6.4 Specialty Clinics
- 13.6.5 Others
- 14 United Kingdom Uveitis Market
- 14.1 United Kingdom Uveitis Market Historical Value (2018-2024)
- 14.2 United Kingdom Uveitis Market Forecast Value (2025-2034)
- 14.3 United Kingdom Uveitis Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Anterior Uveitis
- 14.3.3 Posterior Uveitis
- 14.3.4 Intermediate Uveitis
- 14.3.5 Panuveitis
- 14.3.6 Others
- 14.4 United Kingdom Uveitis Market (2018-2034) by Treatment
- 14.4.1 Market Overview
- 14.4.2 Anti-inflammatory
- 14.4.3 Immunosuppressive
- 14.4.4 Antibiotics
- 14.4.5 Others
- 14.5 United Kingdom Uveitis Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 United Kingdom Uveitis Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospital
- 14.6.3 Homecare
- 14.6.4 Specialty Clinics
- 14.6.5 Others
- 15 Germany Uveitis Market
- 15.1 Germany Uveitis Market Historical Value (2018-2024)
- 15.2 Germany Uveitis Market Forecast Value (2025-2034)
- 15.3 Germany Uveitis Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Anterior Uveitis
- 15.3.3 Posterior Uveitis
- 15.3.4 Intermediate Uveitis
- 15.3.5 Panuveitis
- 15.3.6 Others
- 15.4 Germany Uveitis Market (2018-2034) by Treatment
- 15.4.1 Market Overview
- 15.4.2 Anti-inflammatory
- 15.4.3 Immunosuppressive
- 15.4.4 Antibiotics
- 15.4.5 Others
- 15.5 Germany Uveitis Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Germany Uveitis Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospital
- 15.6.3 Homecare
- 15.6.4 Specialty Clinics
- 15.6.5 Others
- 16 France Uveitis Market (218-2034)
- 16.1 France Uveitis Market Historical Value (2018-2024)
- 16.2 France Uveitis Market Forecast Value (2025-2034)
- 16.3 France Uveitis Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Anterior Uveitis
- 16.3.3 Posterior Uveitis
- 16.3.4 Intermediate Uveitis
- 16.3.5 Panuveitis
- 16.3.6 Others
- 16.4 France Uveitis Market (2018-2034) by Treatment
- 16.4.1 Market Overview
- 16.4.2 Anti-inflammatory
- 16.4.3 Immunosuppressive
- 16.4.4 Antibiotics
- 16.4.5 Others
- 16.5 France Uveitis Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 France Uveitis Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospital
- 16.6.3 Homecare
- 16.6.4 Specialty Clinics
- 16.6.5 Others
- 17 Italy Uveitis Market
- 17.1 Italy Uveitis Market Historical Value (2018-2024)
- 17.2 Italy Uveitis Market Forecast Value (2025-2034)
- 17.3 Italy Uveitis Market (2018-2034) by Type
- 17.3.1 Market Overview
- 17.3.2 Anterior Uveitis
- 17.3.3 Posterior Uveitis
- 17.3.4 Intermediate Uveitis
- 17.3.5 Panuveitis
- 17.3.6 Others
- 17.4 Italy Uveitis Market (2018-2034) by Treatment
- 17.4.1 Market Overview
- 17.4.2 Anti-inflammatory
- 17.4.3 Immunosuppressive
- 17.4.4 Antibiotics
- 17.4.5 Others
- 17.5 Italy Uveitis Market (2018-2034) by Route of Administration
- 17.5.1 Market Overview
- 17.5.2 Oral
- 17.5.3 Parenteral
- 17.5.4 Others
- 17.6 Italy Uveitis Market (2018-2034) by End User
- 17.6.1 Market Overview
- 17.6.2 Hospital
- 17.6.3 Homecare
- 17.6.4 Specialty Clinics
- 17.6.5 Others
- 18 Spain Uveitis Market
- 18.1 Spain Uveitis Market Historical Value (2018-2024)
- 18.2 Spain Uveitis Market Forecast Value (2025-2034)
- 18.3 Spain Uveitis Market (2018-2034) by Type
- 18.3.1 Market Overview
- 18.3.2 Anterior Uveitis
- 18.3.3 Posterior Uveitis
- 18.3.4 Intermediate Uveitis
- 18.3.5 Panuveitis
- 18.3.6 Others
- 18.4 Spain Uveitis Market (2018-2034) by Treatment
- 18.4.1 Market Overview
- 18.4.2 Anti-inflammatory
- 18.4.3 Immunosuppressive
- 18.4.4 Antibiotics
- 18.4.5 Others
- 18.5 Spain Uveitis Market (2018-2034) by Route of Administration
- 18.5.1 Market Overview
- 18.5.2 Oral
- 18.5.3 Parenteral
- 18.5.4 Others
- 18.6 Spain Uveitis Market (2018-2034) by End User
- 18.6.1 Market Overview
- 18.6.2 Hospital
- 18.6.3 Homecare
- 18.6.4 Specialty Clinics
- 18.6.5 Others
- 19 Japan Uveitis Market
- 19.1 Japan Uveitis Market Historical Value (2018-2024)
- 19.2 Japan Uveitis Market Forecast Value (2025-2034)
- 19.3 Japan Uveitis Market (2018-2034) by Type
- 19.3.1 Market Overview
- 19.3.2 Anterior Uveitis
- 19.3.3 Posterior Uveitis
- 19.3.4 Intermediate Uveitis
- 19.3.5 Panuveitis
- 19.3.6 Others
- 19.4 Japan Uveitis Market (2018-2034) by Treatment
- 19.4.1 Market Overview
- 19.4.2 Anti-inflammatory
- 19.4.3 Immunosuppressive
- 19.4.4 Antibiotics
- 19.4.5 Others
- 19.5 Japan Uveitis Market (2018-2034) by Route of Administration
- 19.5.1 Market Overview
- 19.5.2 Oral
- 19.5.3 Parenteral
- 19.5.4 Others
- 19.6 Japan Uveitis Market (2018-2034) by End User
- 19.6.1 Market Overview
- 19.6.2 Hospital
- 19.6.3 Homecare
- 19.6.4 Specialty Clinics
- 19.6.5 Others
- 20 India Uveitis Market
- 20.1 India Uveitis Market Historical Value (2018-2024)
- 20.2 India Uveitis Market Forecast Value (2025-2034)
- 20.3 India Uveitis Market (2018-2034) by Type
- 20.3.1 Market Overview
- 20.3.2 Anterior Uveitis
- 20.3.3 Posterior Uveitis
- 20.3.4 Intermediate Uveitis
- 20.3.5 Panuveitis
- 20.3.6 Others
- 20.4 India Uveitis Market (2018-2034) by Treatment
- 20.4.1 Market Overview
- 20.4.2 Anti-inflammatory
- 20.4.3 Immunosuppressive
- 20.4.4 Antibiotics
- 20.4.5 Others
- 20.5 India Uveitis Market (2018-2034) by Route of Administration
- 20.5.1 Market Overview
- 20.5.2 Oral
- 20.5.3 Parenteral
- 20.5.4 Others
- 20.6 India Uveitis Market (2018-2034) by End User
- 20.6.1 Market Overview
- 20.6.2 Hospital
- 20.6.3 Homecare
- 20.6.4 Specialty Clinics
- 20.6.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Cancer Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 Abbvie Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Developments
- 27.2.5 Certifications
- 27.3 Novartis AG
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Developments
- 27.3.5 Certifications
- 27.4 Bausch Health Companies Inc.
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Developments
- 27.4.5 Certifications
- 27.5 EyePoint Pharmaceuticals, Inc.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Developments
- 27.5.5 Certifications
- 27.6 Santen Pharmaceutical Co., Ltd.
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Developments
- 27.6.5 Certifications
- 27.7 Alimera Sciences, Inc.
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Developments
- 27.7.5 Certifications
- 27.8 Aldeyra Therapeutics, Inc.
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Developments
- 27.8.5 Certifications
- 27.9 Lux Biosciences, Inc.
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Developments
- 27.9.5 Certifications
- 27.10 Hoffmann-La Roche AG
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Developments
- 27.10.5 Certifications
- 27.11 Amgen Inc.
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Developments
- 27.11.5 Certifications
- 28 Global Uveitis Market – Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
